Skip Navigation

European Heart Journal 1996 17(Supplement E):9-13; doi:10.1093/eurheartj/17.suppl_E.9
Copyright © 1996 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Armstrong, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armstrong, P. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 1996 The European Society of Cardiology

Perspectives gained from large-scale thrombolytic comparative trials

P. W. Armstrong

Division of Cardiology, Department of Medicine, University of Alberta Edmonton, Alberta, Canada

Correspondence: P. W. Armstrong, MD, Division of Cardiology, Department of Medicine 2F1.30 WMC, University of Alberta, Edmonton, Alberta, Canada T6G 2R7

Four thrombolytic comparative trials without a placebo arm have each been conducted in populations of more than 1000 patients: GISSI-2 International, ISIS-3, GUSTO, and INJECT. The treatment strategy associated with use of intravenous heparin and the accelerated regimen of tissue plasininogen activator (t-PA) accounts for the differences between the results of GUSTO and those of the earlier studies of GISSI-2 International and ISIS-3. Using analysis of predefined parameters, it is possible to identify those subsets of patients most likely to benefit from accelerated administration of t-PA. A useful profile of patients at risk for intracranial haemorrhage has also been derived; this profile enhances efficient, sensible, individualizeddecision making.

Results from the angiographic substudy of GUSTO highlight the fundamental importance of early coronary artery patency as a determinant of improved left ventricular function and survival and reaffirm the usefulness of left ventricular function as a surrogate measure for assessing the efficacy of novel reperfusion strategies. In addition, the opportunity to evaluate international differences in practice patterns, coupled with measures of quality of life and return to work, has given new insight into the importance of these issues in the care of patients with acute myocardial infarction.

Future investigation must address the challenge of optimal use of resources in assessing novel therapies. Strategies include logistic modelling, surrogate end-points, sample enrichment with high-risk subsets, blended end-points, and uneven randomization.

Key Words: Thrombolytics • myocardial infarction • t-PA • heparin • streptokinase • reteplase


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.